BX 471CCR1 antagonist,potent and selective CAS# 217645-70-0 |
- Calyculin A
Catalog No.:BCC2457
CAS No.:101932-71-2
- Calcineurin Autoinhibitory Peptide
Catalog No.:BCC2456
CAS No.:148067-21-4
- DL-AP3
Catalog No.:BCC2459
CAS No.:20263-06-3
- Ceramide
Catalog No.:BCC2458
CAS No.:3102-57-6
- Fostriecin sodium salt
Catalog No.:BCC2460
CAS No.:87860-39-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 217645-70-0 | SDF | Download SDF |
PubChem ID | 512282 | Appearance | Powder |
Formula | C21H24ClFN4O3 | M.Wt | 434.89 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 51 mg/mL (117.27 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | [5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]urea | ||
SMILES | CC1CN(CCN1C(=O)COC2=C(C=C(C=C2)Cl)NC(=O)N)CC3=CC=C(C=C3)F | ||
Standard InChIKey | XQYASZNUFDVMFH-CQSZACIVSA-N | ||
Standard InChI | InChI=1S/C21H24ClFN4O3/c1-14-11-26(12-15-2-5-17(23)6-3-15)8-9-27(14)20(28)13-30-19-7-4-16(22)10-18(19)25-21(24)29/h2-7,10,14H,8-9,11-13H2,1H3,(H3,24,25,29)/t14-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1). Exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. Inhibits MIP-α/CCL3-induced intracellular Ca2+ mobilization. Orally active; effectively reduces disease severity in a rat model of multiple sclerosis. Decreases renal fibrosis in a mouse model of obstructive nephropathy. |
BX 471 Dilution Calculator
BX 471 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2994 mL | 11.4972 mL | 22.9943 mL | 45.9886 mL | 57.4858 mL |
5 mM | 0.4599 mL | 2.2994 mL | 4.5989 mL | 9.1977 mL | 11.4972 mL |
10 mM | 0.2299 mL | 1.1497 mL | 2.2994 mL | 4.5989 mL | 5.7486 mL |
50 mM | 0.046 mL | 0.2299 mL | 0.4599 mL | 0.9198 mL | 1.1497 mL |
100 mM | 0.023 mL | 0.115 mL | 0.2299 mL | 0.4599 mL | 0.5749 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ki: 1 nM to 5.5 nM
The CC chemokine receptor-1 (CCR1) is a prime therapeutic target for treating autoimmune diseases. BX 471 is a potent, selective, and orally active antagonist of the CC Chemokine Receptor-1.
In vitro: Competition binding studies revealed that BX 471 was able to displace the CCR1 ligands macrophage inflammatory protein-1a, RANTES, and monocyte chemotactic protein-3 with high affinity. BX 471 was a potent functional antagonist based on its ability to inhibit plenty of CCR1-mediated effects. BX 471 also demonstrated a greater than 10,000-fold selectivity for CCR1 compared with 28 G-protein-coupled receptors [1].
In vivo: Pharmacokinetic studies demonstrated that BX 471 was orally active with a 60% bioavailability in dogs. Furthermore, in a rat experimental allergic encephalomyelitis model of multiple sclerosis, BX 471 effectively reduces disease [1].
Clinical trial: Up to now, BX 471 is still in the preclinical development stage.
Reference:
[1] Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S, Bauman JG, Islam I, Ghannam A, Buckman B, Shaw K, Wei GP, Xu W, Zhao Z, Ho E, Shen J, Oanh H, Subramanyam B, Vergona R, Taub D, Dunning L, Harvey S, Snider RM, Hesselgesser J, Morrissey MM, Perez HD. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000 Jun 23;275(25):19000-8.
- Taxoquinone
Catalog No.:BCN6660
CAS No.:21764-41-0
- Cyclo(Ala-Tyr)
Catalog No.:BCN2412
CAS No.:21754-26-7
- Cyclo(Tyr-Val)
Catalog No.:BCN2413
CAS No.:21754-25-6
- Tulathromycin A
Catalog No.:BCC2019
CAS No.:217500-96-4
- L-817,818
Catalog No.:BCC7221
CAS No.:217480-27-8
- L-803,087 trifluoroacetate
Catalog No.:BCC7220
CAS No.:217480-26-7
- Lucidumol A
Catalog No.:BCN8270
CAS No.:217476-73-8
- 1-Hydroxy-2-oxopomolic acid
Catalog No.:BCN4931
CAS No.:217466-37-0
- (±)-J 113397
Catalog No.:BCC7423
CAS No.:217461-40-0
- SB 268262
Catalog No.:BCC7916
CAS No.:217438-17-0
- 5-Methoxyresorcinol
Catalog No.:BCN6904
CAS No.:2174-64-3
- 5-O-Demethylnobiletin
Catalog No.:BCN2958
CAS No.:2174-59-6
- 4-Cadinen-7-ol
Catalog No.:BCN4932
CAS No.:217650-27-6
- H-Asp(OBzl)-OH
Catalog No.:BCC2885
CAS No.:2177-63-1
- 9,16-Dioxo-10,12,14-octadecatrienoic acid
Catalog No.:BCN1490
CAS No.:217810-46-3
- Curcolonol
Catalog No.:BCN3558
CAS No.:217817-09-9
- Diallyl disulfide
Catalog No.:BCN3840
CAS No.:2179-57-9
- Homomangiferin
Catalog No.:BCN8145
CAS No.:21794-66-1
- Noroxyhydrastinine
Catalog No.:BCN2646
CAS No.:21796-14-5
- Thalifoline
Catalog No.:BCN3301
CAS No.:21796-15-6
- Potassium Canrenoate
Catalog No.:BCC3844
CAS No.:2181-04-6
- Isopteleine
Catalog No.:BCN7067
CAS No.:2181-84-2
- SC 26196
Catalog No.:BCC7880
CAS No.:218136-59-5
- SRPIN340
Catalog No.:BCC4849
CAS No.:218156-96-8
BX-471 Berlex.[Pubmed:12137405]
Curr Opin Investig Drugs. 2002 Jun;3(6):865-9.
Berlex and its parent company, Schering AG, are developing BX-471 (also known as ZK-811752), the lead in a series of non-peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS) [291682], [376290], [411184]. In March 2000, BX-471 was undergoing phase I trials for the potential treatment of autoimmune diseases [362022]; phase I trials in MS were ongoing in March 2002 [441989], [443941]. Positive results from these trials have been reported and Berlex was planning phase II trials in MS patients as of mid-March 2002 [444906]. In July 2001, Schering estimated filing in the US and EU in 2008 [411184], [416493]. WO-09856771 claims piperazinyl derivatives, pharmaceutical compositions comprising them and their use in the treatment of inflammatory conditions.
Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation.[Pubmed:16837468]
J Biol Chem. 2006 Sep 15;281(37):27613-20.
A major challenge in the application of structure-based drug design methods to proteins belonging to the superfamily of G protein-coupled receptors (GPCRs) is the paucity of structural information (1). The 19 chemokine receptors, belonging to the Class A family of GPCRs, are important drug targets not only for autoimmune diseases like multiple sclerosis but also for the blockade of human immunodeficiency virus type 1 entry (2). Using the MembStruk computational method (3), we predicted the three-dimensional structure of the human CCR1 receptor. In addition, we predicted the binding site of the small molecule CCR1 antagonist BX 471, which is currently in Phase II clinical trials (4). Based on the predicted antagonist binding site we designed 17 point mutants of CCR1 to validate the predictions. Subsequent competitive ligand binding and chemotaxis experiments with these mutants gave an excellent correlation to these predictions. In particular, we find that Tyr-113 and Tyr-114 on transmembrane domain 3 and Ile-259 on transmembrane 6 contribute significantly to the binding of BX 471. Finally, we used the predicted and validated structure of CCR1 in a virtual screening validation of the Maybridge data base, seeded with selective CCR1 antagonists. The screen identified 63% of CCR1 antagonists in the top 5% of the hits. Our results indicate that rational drug design for GPCR targets is a feasible approach.
Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury.[Pubmed:19050287]
J Immunol. 2008 Dec 15;181(12):8670-6.
Neutrophils and macrophages rapidly infiltrate the kidney after renal ischemia-reperfusion injury, however specific molecular recruitment mechanisms have not been fully delineated for these cell types. Here we provide genetic and pharmacologic evidence supporting a positive role for the chemokine receptor CCR1 in macrophage and neutrophil infiltration in a 7 day mouse model of renal ischemia-reperfusion injury. By day 7, injured kidneys from mice lacking CCR1 contained 35% fewer neutrophils and 45% fewer macrophages than injured kidneys from wild-type control mice. Pretreatment of wild-type mice with the specific CCR1 antagonist BX471 also suppressed neutrophil and macrophage infiltration in the model. Injured kidneys from mice lacking CCR1 also had reduced content of the CCR1 ligands CCL3 (MIP-1alpha) and CCL5 (RANTES) compared with injured kidneys from wild-type controls, suggesting a leukocyte source for these inflammatory chemokines and existence of a CCR1-dependent positive feedback loop for leukocyte infiltration in the model. Local leukocyte proliferation and apoptosis were detected after injury, but were not dependent on CCR1. Also, the extent of necrotic and fibrotic damage and decline in renal function in injured kidneys was similar in wild-type and CCR1-deficient mice. Thus, CCR1 appears to regulate trafficking of macrophages and neutrophils to kidney in a mouse model of renal ischemia-reperfusion injury, however this activity does not appear to affect tissue injury.
A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation.[Pubmed:11805137]
J Clin Invest. 2002 Jan;109(2):251-9.
The expression of chemokines and their receptors is thought to contribute to leukocyte infiltration and progressive renal fibrosis after unilateral ureter obstruction (UUO). We hypothesized that blocking the chemokine receptor CCR1 using the nonpeptide antagonist BX471 could reduce leukocyte infiltration and renal fibrosis after UUO. UUO kidneys from BX471-treated mice (day 0-10 and day 6-10) revealed a 40-60% reduction of interstitial macrophage and lymphocyte infiltrate compared with controls. Treated mice also showed a marked reduction of CCR1 and CCR5 mRNA levels, and FACS analysis showed a comparable reduction of CD8+/CCR5+ T cells. Markers of renal fibrosis, such as interstitial fibroblasts, interstitial volume, mRNA and protein expression for collagen I, were all significantly reduced by BX471-treatment compared with vehicle controls. By contrast treatment was ineffective when the drug was supplied only from days 0 to 5. In summary, blockade of CCR1 substantially reduces cell accumulation and renal fibrosis after UUO. Most interestingly, late onset of treatment is also effective. We therefore conclude that CCR1 blockade may represent a new therapeutic strategy for reducing cellular infiltration and renal fibrosis as major factors in the progression to end-stage renal failure.
Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1.[Pubmed:10748002]
J Biol Chem. 2000 Jun 23;275(25):19000-8.
The CC chemokine receptor-1 (CCR1) is a prime therapeutic target for treating autoimmune diseases. Through high capacity screening followed by chemical optimization, we identified a novel non-peptide CCR1 antagonist, R-N-[5-chloro-2-[2-[4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl ]-2-oxoethoxy]phenyl]urea hydrochloric acid salt (BX 471). Competition binding studies revealed that BX 471 was able to displace the CCR1 ligands macrophage inflammatory protein-1alpha (MIP-1alpha), RANTES, and monocyte chemotactic protein-3 (MCP-3) with high affinity (K(i) ranged from 1 nm to 5.5 nm). BX 471 was a potent functional antagonist based on its ability to inhibit a number of CCR1-mediated effects including Ca(2+) mobilization, increase in extracellular acidification rate, CD11b expression, and leukocyte migration. BX 471 demonstrated a greater than 10,000-fold selectivity for CCR1 compared with 28 G-protein-coupled receptors. Pharmacokinetic studies demonstrated that BX 471 was orally active with a bioavailability of 60% in dogs. Furthermore, BX 471 effectively reduces disease in a rat experimental allergic encephalomyelitis model of multiple sclerosis. This study is the first to demonstrate that a non-peptide chemokine receptor antagonist is efficacious in an animal model of an autoimmune disease. In summary, we have identified a potent, selective, and orally available CCR1 antagonist that may be useful in the treatment of chronic inflammatory diseases.